1. Home
  2. LNC vs IONS Comparison

LNC vs IONS Comparison

Compare LNC & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LNC
  • IONS
  • Stock Information
  • Founded
  • LNC 1905
  • IONS 1989
  • Country
  • LNC United States
  • IONS United States
  • Employees
  • LNC N/A
  • IONS N/A
  • Industry
  • LNC Life Insurance
  • IONS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LNC Finance
  • IONS Health Care
  • Exchange
  • LNC Nasdaq
  • IONS Nasdaq
  • Market Cap
  • LNC 7.9B
  • IONS 6.8B
  • IPO Year
  • LNC N/A
  • IONS 1991
  • Fundamental
  • Price
  • LNC $39.41
  • IONS $61.33
  • Analyst Decision
  • LNC Hold
  • IONS Buy
  • Analyst Count
  • LNC 10
  • IONS 17
  • Target Price
  • LNC $39.30
  • IONS $67.88
  • AVG Volume (30 Days)
  • LNC 1.7M
  • IONS 3.3M
  • Earning Date
  • LNC 10-30-2025
  • IONS 11-05-2025
  • Dividend Yield
  • LNC 4.61%
  • IONS N/A
  • EPS Growth
  • LNC N/A
  • IONS N/A
  • EPS
  • LNC 6.00
  • IONS N/A
  • Revenue
  • LNC $18,036,000,000.00
  • IONS $944,050,000.00
  • Revenue This Year
  • LNC $7.14
  • IONS $24.30
  • Revenue Next Year
  • LNC $4.19
  • IONS $7.39
  • P/E Ratio
  • LNC $6.51
  • IONS N/A
  • Revenue Growth
  • LNC 31.97
  • IONS 16.05
  • 52 Week Low
  • LNC $27.58
  • IONS $23.95
  • 52 Week High
  • LNC $43.66
  • IONS $64.72
  • Technical
  • Relative Strength Index (RSI)
  • LNC 40.58
  • IONS 72.40
  • Support Level
  • LNC $41.02
  • IONS $60.64
  • Resistance Level
  • LNC $42.45
  • IONS $64.61
  • Average True Range (ATR)
  • LNC 1.00
  • IONS 2.40
  • MACD
  • LNC -0.48
  • IONS 0.67
  • Stochastic Oscillator
  • LNC 7.63
  • IONS 85.10

About LNC Lincoln National Corporation

Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: